Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682213e7a0295-trace').style.display = (document.getElementById('cakeErr682213e7a0295-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr682213e7a0295-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682213e7a0295-code').style.display = (document.getElementById('cakeErr682213e7a0295-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr682213e7a0295-context').style.display = (document.getElementById('cakeErr682213e7a0295-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr682213e7a0295-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr682213e7a0295-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 10393,
		&#039;title&#039; =&gt; &#039;Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.
&lt;/div&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Mainstream Weekly, Vol XLIX, No 41, October 1, 2011, http://www.mainstreamweekly.net/article3037.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 10504,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 10393,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.&lt;/div&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 10393,
	&#039;title&#039; =&gt; &#039;Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.
&lt;/div&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Mainstream Weekly, Vol XLIX, No 41, October 1, 2011, http://www.mainstreamweekly.net/article3037.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 10504,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 10393
$metaTitle = &#039;LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.&lt;/div&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra | Im4change.org</title>
    <meta name="description" content="




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Medicines: For Saving Life or For Superprofits? by Bharat Dogra</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify"><div style="text-align: justify"><br /></div><div style="text-align: justify">Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.</div></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682213e7a0295-trace').style.display = (document.getElementById('cakeErr682213e7a0295-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr682213e7a0295-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682213e7a0295-code').style.display = (document.getElementById('cakeErr682213e7a0295-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr682213e7a0295-context').style.display = (document.getElementById('cakeErr682213e7a0295-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr682213e7a0295-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr682213e7a0295-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 10393,
		&#039;title&#039; =&gt; &#039;Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.
&lt;/div&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Mainstream Weekly, Vol XLIX, No 41, October 1, 2011, http://www.mainstreamweekly.net/article3037.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 10504,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 10393,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.&lt;/div&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 10393,
	&#039;title&#039; =&gt; &#039;Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.
&lt;/div&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Mainstream Weekly, Vol XLIX, No 41, October 1, 2011, http://www.mainstreamweekly.net/article3037.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 10504,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 10393
$metaTitle = &#039;LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.&lt;/div&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra | Im4change.org</title>
    <meta name="description" content="




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Medicines: For Saving Life or For Superprofits? by Bharat Dogra</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify"><div style="text-align: justify"><br /></div><div style="text-align: justify">Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.</div></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682213e7a0295-trace').style.display = (document.getElementById('cakeErr682213e7a0295-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr682213e7a0295-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682213e7a0295-code').style.display = (document.getElementById('cakeErr682213e7a0295-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr682213e7a0295-context').style.display = (document.getElementById('cakeErr682213e7a0295-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr682213e7a0295-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr682213e7a0295-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 10393,
		&#039;title&#039; =&gt; &#039;Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.
&lt;/div&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Mainstream Weekly, Vol XLIX, No 41, October 1, 2011, http://www.mainstreamweekly.net/article3037.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 10504,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 10393,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.&lt;/div&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 10393,
	&#039;title&#039; =&gt; &#039;Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.
&lt;/div&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Mainstream Weekly, Vol XLIX, No 41, October 1, 2011, http://www.mainstreamweekly.net/article3037.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 10504,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 10393
$metaTitle = &#039;LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&amp;rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&amp;rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.&lt;/div&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra | Im4change.org</title>
    <meta name="description" content="




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Medicines: For Saving Life or For Superprofits? by Bharat Dogra</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify"><div style="text-align: justify"><br /></div><div style="text-align: justify">Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.</div></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 10393,
		'title' => 'Medicines: For Saving Life or For Superprofits? by Bharat Dogra',
		'subheading' => '',
		'description' => '<div style="text-align: justify">
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.
</div>
</div>',
		'credit_writer' => 'Mainstream Weekly, Vol XLIX, No 41, October 1, 2011, http://www.mainstreamweekly.net/article3037.html',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 10504,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 10393,
	'metaTitle' => 'LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra',
	'metaKeywords' => 'Health',
	'metaDesc' => '




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated...',
	'disp' => '<div style="text-align: justify"><div style="text-align: justify"><br /></div><div style="text-align: justify">Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.</div></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 10393,
	'title' => 'Medicines: For Saving Life or For Superprofits? by Bharat Dogra',
	'subheading' => '',
	'description' => '<div style="text-align: justify">
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.
</div>
</div>',
	'credit_writer' => 'Mainstream Weekly, Vol XLIX, No 41, October 1, 2011, http://www.mainstreamweekly.net/article3037.html',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'medicines-for-saving-life-or-for-superprofits-by-bharat-dogra-10504',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 10504,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 10393
$metaTitle = 'LATEST NEWS UPDATES | Medicines: For Saving Life or For Superprofits? by Bharat Dogra'
$metaKeywords = 'Health'
$metaDesc = '




Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated...'
$disp = '<div style="text-align: justify"><div style="text-align: justify"><br /></div><div style="text-align: justify">Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it&rsquo;ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can&rsquo;t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.</div></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Medicines: For Saving Life or For Superprofits? by Bharat Dogra

Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage. It may be pointed out here that as early as 2006 many prominent persons and organisations from all over the world had petitioned the Chairman of Novartis, the multinational company which produces Glivec, to drop the pursuit of its case for patent right over this medicine. But the multinational giant has obviously not given up even after the rejection of its patent claim by the Chennai Patent Office, the Madras High Court and the Intellectual Property Appellate Board during the period 2006-09. The case is now in the Supreme Court. As patients diagnosed for chronic myeloid leukemia have to take Glivec (imatinib mesylate) for the rest of their life, the price of this medicine is of crucial importance for deciding whether it’ll be affordable for most patients or not. While Indian companies producing generic versions of this medicine are able to supply this at the rate of about Rs one lakh per patient per year, Novartis markets Glivec internationally at a price which can cost patients about 12 times that amount. Clearly if generic versions are not available, then this medicine will be priced out of the reach of most patients not only in India but also in many other poor and developing countries, as the supply in these other countries is also based on exports of Indian companies. Of course, many patients can’t even afford the generic versions, but several charitable and health organisations are able to provide them the generic versions. But if due to patents the prices increase many times, then the budgets of these organisations will clearly not be adequate to maintain these supplies. Thus this is a clear case for questioning whether the superprofits of a company are more important than the lives of lakhs of patients. Clearly in all such cases it is the right to life which is supreme. The significance of this case is not confined to cancer patients. If the claim for patent rights is allowed to lead to a steep escalation of this life-saving drug, then tomorrow a similar increase can take place in the price of medicines for HIV-AIDS, heart diseases etc. In fact even the technical claim for patents in the case of several such medicines is highly dubious as there are mainly refined or toned-up versions of already existing medicines. At the time of the earlier debate on Trade-Related Intellectual Property Rights (TRIPS) and the World Trade Organisation (WTO), it was pointed out that many of the new rules will be heavily detrimental for the health sector. So there needs to be a wider campaign against TRIPS as well as the heavy penetration of the medicine sector by multinational companies. The more this domination is allowed to increase and the bigger the withdrawal of the public sector manufacturers and regulatory framework, the more difficult will it become for the common people to obtain essential medicines at affordable prices.